Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × INDUSTRY × Disease × Clear all

Phase

Phase NA 8 Phase 2 8 Phase 3 6 Phase 1 6 Phase 1/2 4 Phase 2/3 1

Status

Sponsor Class

OTHER_GOV 1 OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 25 Neoplasms 21 Neoplasm Metastasis 18 Breast Neoplasms 18 Prostatic Neoplasms 14 Colorectal Neoplasms 13 Stomach Neoplasms 12 Recurrence 12 Squamous Cell Carcinoma of Head and Neck 10 Pancreatic Neoplasms 10 Ovarian Neoplasms 10 Lung Neoplasms 10 Head and Neck Neoplasms 10 Myasthenia Gravis 9 Carcinoma, Hepatocellular 9 Urinary Bladder Neoplasms 8 Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Melanoma 7 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Follicular 5 Liver Neoplasms 5 Glioblastoma 5 Colonic Neoplasms 5 Carcinoma, Transitional Cell 5 Small Cell Lung Carcinoma 4 Myelodysplastic Syndromes 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02981368 2021-08-09

OSPREY

Progenics Pharmaceuticals, Inc.

Phase 2/3 Completed

385 enrolled 20 charts

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡